# US 2021/0071272 A1 · Assay for detecting closely-related serotypes of human papillomavirus (hpv)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0071272 A1
- Document ID: US20210071272A1
- Status: Published application
- Kind: A1
- Application number: 17/094,908
- Filed: 2020-11-11
- Published: 2021-03-11
- Earliest claimed: 2010-02-16
- Assignees: Becton, Dickinson and Company
- Applicants: Becton Dickinson and Company
- Inventors: Chi Chen; Hugh J. Peck; Michael Porter; Gregory A. Richart; Ray A. Mc Millian
- Web page: https://patentgrep.com/patent/US20210071272A1

## CPC

- C12Q 1/708: {for papilloma}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A real time Taq-Man PCR assay for detecting multiple serotypes of human papillomavirus (HPV) wherein the number of serotypes detected exceeds the number of colorimetric channels for detection. A biological sample is combined with three oligonucleotide primer/probe sets such that the probes and primers anneal to a target sequence. Each primer/probe set is at least preferential for a specific serotype of an organism. The first and second primer/probe sets are degenerate with respect to each other. The third primer/probe set is not degenerate with respect to the first and second primer/probe sets and discriminates for a third serotype. The third primer/probe set has a signal moiety that emits signal at a wavelength that is the same or different from the wavelength emitted by the signal moiety of the degenerate primer/probe set probes. The target sequences, if present, are amplified and detected.

## Claims

### Claim at position 1

1-12. (canceled)

### Claim 13

A probe set for the detection of multiple serotypes of human papillomavirus (HPV) comprising at least three oligonucleotide primer/probe sets, each of which comprises at least one oligonucleotide probe that is detectably labeled and has a nucleotide sequence length of about 10 to about 50 and at least two oligonucleotide primers each of which has a nucleotide sequence length of about 10 to about 150 wherein each primer/probe set is at least preferential for a specific serotype of the HPV organism wherein the first and second of the primer/probe sets are degenerate with respect to each other and wherein the degenerate probes each have a signal moiety that emits signal that is detectable on the same channel and wherein the third primer/probe set is not degenerate with respect to the first and second primer/probe sets and discriminates for a third serotype that is not the serotypes to which the degenerate primer/probe sets preferentially anneal and wherein the third primer/probe set has a signal moiety that emits signal at a wavelength that is the same or different from the wavelength of the probes in the first and second primer/probe sets.

### Claim 14 (depends on 13)

The probe set of claim 13 wherein the degenerate primer/probe set target is selected from the group consisting of SEQ ID NOS: 36-38.

### Claim 15 (depends on 13)

The probe set of claim 13 wherein the degenerate primer/probe set target is SEQ ID NO: 36 and wherein the third primer/probe set is configured to discriminate for HPV serotype 51 and is not degenerate with respect to the first or second primer/probe set, wherein the third primer/probe set is selected from at least one of the sequences selected from the group consisting of SEQ ID NOS: 24-29 and sequences that are at least 70% homologous to SEQ ID NOS: 24-29; the first primer/probe set selects for HPV serotype 39 and does not discriminate for HPV 39 serotype with respect to HPV serotype 68, wherein the first primer/probe set is selected from at least one of the sequences selected from the group consisting of SEQ ID NOS: 1, 3 and 5 and sequences that are at least 70% homologous to SEQ ID NOS: 1, 3 and 5; and the second primer/probe set selects for HPV serotype 68 and does not discriminate for HPV 68 serotype with respect to HPV serotype 39, wherein the second primer/probe set is selected from at least one of the sequences selected from the group consisting of SEQ ID NOS: 2, 4 and 6 and sequences that are at least 70% homologous to SEQ ID NOS: 2, 4 and 6.

### Claim 16 (depends on 13)

The probe set of claim 13 wherein the degenerate primer/probe set target is SEQ ID NO: 37 and wherein the third primer/probe set is configured to discriminate for HPV serotype 59 and is not degenerate with respect to the first or second primer/probe set, wherein the primer/probe set is selected from at least one of the sequences selected from the group consisting of SEQ ID NOS: 30-35 and sequences that are at least 70% homologous to SEQ ID NOS: 30-35; the first primer/probe set selects for HPV serotype 33 and does not discriminate for HPV 33 serotype with respect to HPV serotype 58, wherein the first primer/probe set is selected from at least of the sequences selected from the group consisting of SEQ ID NOS: 7, 9, 11, 13, and 15 and sequences that are at least 70% homologous to SEQ ID NOS: 7, 9, 11, 13, and 15; and the third primer/probe set selects for HPV serotype 58 and does not discriminate for HPV 58 serotype with respect to HPV serotype 33, wherein the second primer/probe set is selected from at least one of the sequences selected from the group consisting of SEQ ID NOS: 8, 10, 12, 14, and 16 and sequences that are at least 70% homologous to SEQ ID NOS: 8, 10, 12, 14, and 16.

### Claim 17 (depends on 13)

The probe set of claim 13 wherein the degenerate primer/probe set target is SEQ ID NO: 38 and wherein the third primer/probe set is configured to discriminate for HPV serotype 59 and is not degenerate with respect to the first or second primer/probe set, wherein the primer/probe set is selected from at least one of the sequences selected from the group consisting of SEQ ID NOS: 30-35 and sequences that are at least 70% homologous to SEQ ID NOS: 30-35; the first primer/probe set selects for HPV serotype 56 and does not discriminate for HPV 66 serotype with respect to HPV serotype 56, wherein the first primer/probe set is selected from at least of the sequences selected from the group consisting of SEQ ID NOS: 17, 19 and 21 and sequences that are at least 70% homologous to SEQ ID NOS: 17, 19 and 21; and the second primer/probe set selects for HPV serotype 66 and does not discriminate for HPV 66 serotype with respect to HPV serotype 56, wherein the second primer/probe set is selected from at least of the sequences selected from the group consisting of SEQ ID NOS: 18, 20, 22, and 23 and sequences that are at least 70% homologous to SEQ ID NOS: 18, 20, 22, and 23.

### Claim 18 (depends on 13)

The probe set of claim 13 wherein the degenerate primer/probe set target is SEQ ID NO: 36 and wherein the third primer/probe set is configured to discriminate for HPV serotype 51 and is not degenerate with respect to the first or second primer/probe set, wherein the primer/probe set is selected from at least one of the sequences selected from the group consisting of SEQ ID NOS: 24-29 and sequences that are at least 80% homologous to SEQ ID NOS: 24-29; the first primer/probe set selects for HPV serotype 39 and does not discriminate for HPV 39 serotype with respect to HPV serotype 68, wherein the first primer/probe set is selected from at least one of the sequences selected from the group consisting of SEQ ID NOS: 1, 3, and 5 and sequences that are at least 80% homologous to SEQ ID NOS: 1, 3, and 5; and the second primer/probe set selects for HPV serotype 68 and does not discriminate for HPV 68 serotype with respect to HPV serotype 39, wherein the second primer/probe set is selected from at least one of the sequences selected from the group consisting of SEQ ID NOS: 2, 4 and 6 and sequences that are at least 80% homologous to SEQ ID NOS: 2, 4, and 6.

### Claim 19 (depends on 13)

The probe set of claim 13 wherein the degenerate primer/probe set target is SEQ ID NO: 37 and wherein the third primer/probe set is configured to discriminate for HPV serotype 59 and is not degenerate with respect to the first or second primer/probe set, wherein the primer/probe set is selected from at least one of the sequences selected from the group consisting of SEQ ID NOS: 30-35 and sequences that are at least 80% homologous to SEQ ID NOS: 30-35; the first primer/probe set selects for HPV serotype 33 and does not discriminate for HPV 33 serotype with respect to HPV serotype 58, wherein the first primer/probe set is selected from at least of the sequences selected from the group consisting of SEQ ID NOS: 7, 9, 11, 13, and 15 and sequences that are at least 80% homologous to SEQ ID NOS: 7, 9, 11, 13, and 15; and the second primer/probe set selects for HPV serotype 58 and does not discriminate for HPV 58 serotype with respect to HPV serotype 33, wherein the second primer/probe set is selected from at least one of the sequences selected from the group consisting of SEQ ID NOS: 8, 10, 12, 14, and 16 and sequences that are at least 80% homologous to SEQ ID NOS: 8, 10, 12, 14, and 16.

### Claim 20 (depends on 13)

The probe set of claim 13 wherein the degenerate primer/probe set target is SEQ ID NO: 38 and wherein the third primer/probe set is configured to discriminate for HPV serotype 59 and is not degenerate with respect to the first or second primer/probe set, wherein the primer/probe set is selected from at least one of the sequences selected from the group consisting of SEQ ID NOS: 30-35 and sequences that are at least 80% homologous to SEQ ID NOS: 30-35; the first primer/probe set selects for HPV serotype 56 and does not discriminate for HPV 66 serotype with respect to HPV serotype 56, wherein the first primer/probe set is selected from at least of the sequences selected from the group consisting of SEQ ID NOS: 17, 19 and 21 and sequences that are at least 80% homologous to SEQ ID NOS: 17, 19 and 21; and the second primer/probe set selects for HPV serotype 66 and does not discriminate for HPV 66 serotype with respect to HPV serotype 56, wherein the second primer/probe set is selected from at least of the sequences selected from the group consisting of SEQ ID NOS: 18, 20, 22, and 23 and sequences that are at least 80% homologous to SEQ ID NOS: 18, 20, 22, and 23.

### Claim 21 (depends on 13)

The probe set of claim 13 wherein the degenerate primer/probe set target is SEQ ID NO: 36 and wherein the third primer/probe set is configured to discriminate for HPV serotype 51 and is not degenerate with respect to the first or second primer/probe set, wherein the primer/probe set is selected from at least one of the sequences selected from the group consisting of SEQ ID NOS: 24-29 and sequences that are at least 90% homologous to SEQ ID NOS: 24-29; the first primer/probe set selects for HPV serotype 39 and does not discriminate for HPV 39 serotype with respect to HPV serotype 68, wherein the first primer/probe set is selected from at least one of the sequences selected from the group consisting of SEQ ID NOS: 1, 3 and 5 and sequences that are at least 90% homologous to SEQ ID NOS: 1, 3 and 5; and the second primer/probe set selects for HPV serotype 68 and does not discriminate for HPV 68 serotype with respect to HPV serotype 39, wherein the second primer/probe set is selected from at least one of the sequences selected from the group consisting of SEQ ID NOS: 2, 4 and 6 and sequences that are at least 90% homologous to SEQ ID NOS: 2, 4 and 6.

### Claim 22 (depends on 13)

The probe set of claim 13 wherein the degenerate primer/probe set target is SEQ ID NO: 37 and wherein the third primer/probe set is configured to discriminate for HPV serotype 59 and is not degenerate with respect to the first or second primer/probe set, wherein the primer/probe set is selected from at least one of the sequences selected from the group consisting of SEQ ID NOS: 30-35 and sequences that are at least 90% homologous to SEQ ID NOS: 30-35; the first primer/probe set selects for HPV serotype 33 and does not discriminate for HPV 33 serotype with respect to HPV serotype 58, wherein the first primer/probe set is selected from at least of the sequences selected from the group consisting of SEQ ID NOS: 7, 9, 11, 13, and 15 and sequences that are at least 90% homologous to SEQ ID NOS: 7, 9, 11, 13, and 15; and the second primer/probe set selects for HPV serotype 58 and does not discriminate for HPV 58 serotype with respect to HPV serotype 33, wherein the second primer/probe set is selected from at least one of the sequences selected from the group consisting of SEQ ID NOS: 8, 10, 12, 14, and 16 and sequences that are at least 90% homologous to SEQ ID NOS: 8, 10, 12, 14, and 16.

### Claim 23 (depends on 13)

The probe set of claim 13 wherein the degenerate primer/probe set target is SEQ ID NO: 38 and wherein the third primer/probe set is configured to discriminate for HPV serotype 59 and is not degenerate with respect to the first or second primer/probe set, wherein the primer/probe set is selected from at least one of the sequences selected from the group consisting of SEQ ID NOS: 30-35 and sequences that are at least 90% homologous to SEQ ID NOS: 30-35; the first primer/probe set selects for HPV serotype 56 and does not discriminate for HPV 66 serotype with respect to HPV serotype 56, wherein the first primer/probe set is selected from at least of the sequences selected from the group consisting of SEQ ID NOS: 17, 19 and 21 and sequences that are at least 90% homologous to SEQ ID NOS: 17, 19 and 21; and the second primer/probe set selects for HPV serotype 66 and does not discriminate for HPV 66 serotype with respect to HPV serotype 56, wherein the second primer/probe set is selected from at least of the sequences selected from the group consisting of SEQ ID NOS: 18, 20, 22, and 23 and sequences that are at least 90% homologous to SEQ ID NOS: 18, 20, 22, and 23.

### Claim 24

A kit for the detection of multiple serotypes of human papillomavirus (HPV) the kit comprising at least three oligonucleotide primer/probe sets, each of which comprises at least one oligonucleotide probe that is detectably labeled and has a nucleotide sequence length of about 10 to about 50 and at least two oligonucleotide primers each of which has a nucleotide sequence length of about 10 to about 150 for a specific serotype of the HPV organism wherein the first and second primer/probe sets are degenerate with respect to each other and wherein the degenerate probes each have a signal moiety that emits signal that is detectable on the same channel and wherein the third primer/probe set is not degenerate with respect to the other two primer/probe sets and discriminates for a third serotype that is not the serotypes to which the degenerate primer/probe sets preferentially anneal and wherein the third primer/probe set has a signal moiety that emits signal at a wavelength that is the same or different from the wavelength emitted by the signal moieties of the probes in the degenerate primer/probe set.

### Claim 25 (depends on 24)

The kit of claim 24 wherein the degenerate primer/probe set target for the first and second degenerate primer/probe sets is selected from the group consisting of one of SEQ ID NOS: 36-38.

### Claim 26 (depends on 24)

The kit of claim 24 wherein the degenerate primer/probe set target is SEQ ID NO: 36 and the first degenerate primer/probe set comprises SEQ ID NOS: 1, 3 and 5 and the second degenerate primer/probe set comprises SEQ ID NOS: 2, 4, and 6.

### Claim 27 (depends on 24)

The kit of claim 24 where the degenerate primer/probe set target is SEQ ID NO: 737 and the first degenerate primer/probe set comprises SEQ ID NO: 7, SEQ ID NO: 15 and one of SEQ ID NOS: 9, 11 and 13 and the second degenerate primer/probe set comprises SEQ ID NO: 8, SEQ ID NO: 15 and one of SEQ ID NOS: 10, 12 and 14.

### Claim 28 (depends on 24)

The kit of claim 24 where the degenerate primer/probe set target is SEQ ID NO: 38 and the first degenerate primer/probe set comprises SEQ ID NOS: 17, 19, and 21 and the second degenerate primer/probe set comprises SEQ ID NO: 18, SEQ ID NO: 20 and one of SEQ ID NO: 22 and 23.

### Claim 29 (depends on 24)

The kit of claim 24 wherein the third primer/probe set is selected from the group consisting of SEQ ID NOS. 24-26, SEQ ID NOS: 27-29, SEQ ID NOS: 30-32 and SEQ ID NOS: 33-35.

### Claim 30 (depends on 29)

The kit of claim 29 wherein the third primer probe set discriminates for HPV serotype 51 and is selected from the group consisting of SEQ ID NOS: 24-26 and SEQ ID NOS: 27-29.

### Claim 31 (depends on 29)

The kit of claim 29 wherein the third primer probe set discriminates for HPV serotype 59 and is selected from the group consisting of SEQ ID NO. SEQ ID NOS: 30-32 and SEQ ID NOS: 33-35.

### Claim 32 (depends on 29)

The kit of claim 29 wherein the signal moiety of the detector probe of the third primer/probe set emits a wavelength that is the same as the wavelength emitted by the detector probe of the first and second primer/probe sets.

### Claim 33 (depends on 29)

The kit of claim 29 wherein the signal moiety of the detector probe of the third primer/probe set emits a wavelength that is different from the wavelength emitted by the detector probe of the first and second primer/probe sets.
